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Abstract
Background. In the general population, pneumococcal polysaccharide vaccines (PPV) decrease
the incidence of invasive pneumococcal disease (IPD) whereas the impact on the prevention of
noninvasive pneumococcal disease is less clear. As compared with PPV, pneumococcal conjugate
vaccines (PCV) provoke a higher, longer-lasting immune response resulting in a 45% decreased
incidence in vaccine-type pneumonia, and a 75% decrease in vaccine-type IPD.
Methods. Literature review on pneumococcal vaccination in end-stage renal disease.
Results. As compared with the general population, patients with chronic kidney disease (CKD)
suffer increased mortality and morbidity from pneumococcal disease (PD), being up to 10-fold for
those treated with dialysis. Numerous, usually small and methodological heterogeneous studies
demonstrate that PPV provokes a serological response in dialysis patients, kidney transplant recipi-
ents, children with nephrotic syndrome and CKD patients receiving immunosuppressive medica-
tion. This response is of less intensity and duration than in healthy controls. Similar observations
were made for the PCV. The protective value of these vaccine-elicited anti-pneumococcal
antibodies in the CKD population remains to be substantiated. For patients treated with dialysis,
epidemiological data demonstrate a correlation—which does not equal causality—between
pneumococcal vaccination status and a slightly decreased total mortality. Clinical outcome data
on the effectiveness of pneumococcal vaccination in the prevention of morbidity and mortality in
the CKD population are lacking.
Conclusions. Awaiting better evidence, pneumococcal vaccination should be advocated in all
patients with CKD, as early in their disease course as possible. The ACIP schedule recommends a
PCV-13 prime vaccination followed by a PPV-23 repeated vaccine at least 8 weeks later in pneumo-
coccal non-vaccinated patients, and a PCV-13 vaccine at least 1 year after the latest PPV vaccine in
previously vaccinated patients. In the UK, vaccination with PPV-23 only is recommended. There
exist no good data supporting re-vaccination after 5 years in the dialysis population.
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Background
In recent years, pneumococcal vaccination was a field in
strong evolution. New conjugated vaccines were licensed,
cohort data on the effect of vaccination on the epidemi-
ology of PD emerged, new assays to evaluate vaccine effi-
cacy were developed and one large population-based
prospective study on the effect of pneumococcal vaccin-
ation (CAPiTA) was recently finished.
This review aims to give an update on pneumococcal
vaccination in nephrological patients. The review starts
with a brief overview of the evidence gathered in the
general population and finishes with a summary of the
available evidence in all groups of CKD patients.
Pneumococcal infections and vaccination
in the general population
Definition, classification and burden of disease
Pneumococcal disease is every infection caused by the
Gram-stain positive coccus Streptococcus pneumonia also
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Clin Kidney J (2015) 8: 318–324
doi: 10.1093/ckj/sfv030
Advance Access publication 7 May 2015
called the pneumococcus. The polysaccharide compos-
ition of the pneumococcal outer capsule distinguishes >93
serotypes that predispose for heterogeneous disease
manifestations and a variable epidemiology across the
world [1, 2]. Colonization of the upper respiratory tract,
frequently occurring in early infancy, universally precedes
infection [2, 3]. Tissue invasion is generally triggered by
local inflammation as seen in the presence of viral infec-
tions and can be prevented when serotype-specific antic-
apsular antibodies with opsonophagocytic capacity are
present [3, 4]. PD is classically divided into noninvasive
and IPD.
Noninvasive pneumococcal disease. Noninvasive pneumo-
coccal diseases are those infections where S. pneumoniae is
only isolated from non-sterile body sites, such as sinusitis,
acute otitis media and non-bacteraemic community-ac-
quired pneumonia (CAP) [1]. Pneumococci cause about
one-quarter of CAP, making CAP the highest burden of PD in
adults [1]. The incidence of CAP is 1.6 to 11.6 per 1000
persons per year [1]. In the German CAPNETZ study, short-
term mortality of pneumococcal CAP varied between 0.3%
in young patients without comorbidity and 26.6% in elderly
residing in a nursing home [5, 6]. In addition, an excess in
mortality as high as 30–50% is observed within the 3–5
years following the survival of an initial episode of CAP [1].
Invasive pneumococcal disease. Invasive pneumococcal
diseases are infections confirmed by the isolation of
S. pneumoniae from a normally sterile body site, such as
blood and cerebrospinal fluid. Consequently, incidence
rates of IPD may vary considerably depending on differ-
ences in local practices in performing blood cultures. In
a Belgian study, bacteraemic pneumonia, meningitis
and primary bacteraemia without obvious focus consisted
of respectively 79, 6 and 6% of the IPD in adults [7, 8].
Thirty-eight percent of IPD occurs in children younger than
2 years, and 54% in adults of >50 years [7, 9]. In adults, IPD
incidence and mortality increase incrementally with age,
ranging from 3.8/100 000/year for adults aged 18–34 years
to 36.4/100 000/year for adults over 65 years of age [7, 9,
10]. Immunocompromised adults are at highest risk, with
incidences of 186 and 173/100 000/year in adults aged 18–
64 years with respectively hematological cancers and HIV
[10]. IPD mortality ranges from 10 to 30% [1, 2]. Before the
introduction of the pneumococcal polysaccharide vaccine
(PCV), pneumococci were the third pathogen in blood-
stream infections (after Escherichia coli and Staphylococcus
aureus), with an incidence of 10/100 000/year [8].
Antibiotic treatment
Pneumococcae are used to be susceptible to all beta-
lactam antibiotics, namely penicillins, cephalosporins and
carbapenems [11]. A 2014 review found decreased peni-
cillin susceptibility in 8.4–20.7% of the isolates, with major
variability among countries [11]. High doses of penicillins
generally remain active against penicillin-intermediate
susceptible infections outside the meningeal compart-
ment. Most isolates remain susceptible to third-gener-
ation cephalosporins and fluoroquinolones. Erythromycin
resistance is high.
Prevention of pneumococcal infections with vaccination
How to evaluate the protective effect of a pneumococcal
vaccine. A long-lasting, well-powered, prospective, ran-
domized controlled trial (RCT) in the population at risk cor-
relating vaccination with the subsequent risk for PD and
all-cause mortality and morbidity is the most robust way
to evaluate the efficacy of pneumococcal vaccination. The
efficacy of the PCV-13 in the elderly has been investigated
according to these requirements in a large RCT known as
the CAPiTA trial [12, 13]. A smaller RCT investigated the ef-
ficacy of PPV-23 against pneumonia and mortality in the
high-risk subpopulation of elderly residing in a nursing
home [14].
Investigators, however, frequently rely on less-robust
methods such as observational studies (case–control and
cohort) and trials with surrogate endpoints such as the
in vitro evaluation of the vaccine immunogenicity [4].
These in vitro methods are, however, diverse and poorly
standardized [4, 15]. Older radioimmunoassays (RIA) are
hard to interpret due to their inability to distinguish non-
neutralizing common cell-wall polysaccharide antibodies
from neutralizing capsular-polysaccharide-specific anti-
bodies. Serotype-specific enzyme-linked immunoabsorbent
assays (ELISA) selectively quantify these neutralizing, cap-
sular-polysaccharide-specific antibodies. Opsonophagocy-
tosis assays (OPA) provide functional information on the
protective effect of serospecific antibodies [15]. ELISA and
OPA assays correlate well in young children, but poorly in
the elderly and in immunocompromised patients [15]. The
serological cutoffs for protection are poorly defined.
The pneumococcal polysaccharide vaccine. The 14-valent
polysaccharide vaccine (PPV-14) was FDA-approved in 1977,
and the 23-valent (PPV-23), containing surface polysacchar-
ide of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F,
14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F, in 1983
[2]. PPVs induce a B-cell response that wanes within 5 years
but remains detectable for >10 years [2, 16].
Data on clinical efficacy of the PPV, summarized in a
2013 Cochrane analysis, demonstrate a protective effect
in reducing IPD in adults, which is less clear in immuno-
compromised and chronically ill patients [17]. PPV pro-
vides protection against presumptive pneumococcal
pneumonia [OR = 0.46 (0.25–0.84)], but the evidence for a
protective effect against all-cause pneumonia is inconclu-
sive [17]. The PPV-23 is poorly immunogenic in infants
and consequently not licensed for under the age of 2 [2].
Most guidelines recommend the PPV-23 for the prevention
of IPD in all adults aged ≥65 years, and for adults at risk
for pneumococcal infections aged 19–64 years [10, 18,
19]. Despite the lack of clinical data and inconclusive im-
munogenicity studies, a re-vaccination after 5 years is
generally recommended [2].
The pneumococcal conjugate vaccine. In the conjugate
vaccine, the pneumococcal polysaccharide antigen is con-
jugated to a protein to enhance immunogenicity, being
either protein D, diphtheria toxoid and tetanus toxoid
carrier proteins for the PCV-10 or the CRM 197 carrier
protein for the PCV-7 and PCV-13 [2]. Conjugate vaccines
elicit a specific B-cell and a T-helper-2 cell response
and induce immunological memory [2]. Conjugate vac-
cines are also immunogenic in younger children and
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immunocompromised adults [2]. The PCV-7 (including
serotype 4, 6B, 9V, 14, 18C, 19F and 23F) was FDA-ap-
proved in 2000. The PCV-13 (additionally covers serotypes
1, 3, 5, 6A, 7F and 19A) nowadays replaced [20] the PCV-7
[1]. Prior vaccination with the PPV negatively affects the
antibody response to subsequent conjugated vaccines, an
effect that is not restored by adding additional doses of
conjugated vaccine [21]. Consequently, a PCV prime–PPV
repeat vaccination (to enhance the number or serotypes)
strategy is recommended [13, 21].
Effectiveness of the conjugate vaccine on the population
level.
The Dutch CAPiTA trial is a prospective, double-blinded,
placebo-controlled RCT, investigating the efficacy of PCV-
13 in ∼85 000 adults older than 65 years without known
immunodeficiency [12, 13]. The CAPiTA trial demonstrates
a highly significant 45.6% [95% CI (21.8–62.5)] reduction
in first episode of vaccine-type CAP, a 45.0% [95% CI
(14.7–65.3)] reduction in first episode of non-bacteraemic/
noninvasive vaccine-type CAP and a 75% [95% CI (41.4–
90.8)] reduction in first episode of vaccine-type IPD, with,
however, no effect on overall mortality [12].
Epidemiological data after the introduction of universal
PCV-7 vaccination in childhood in the UK demonstrate a
98% reduction of vaccine-type PD in children younger
than 2 years, and of 81% in adults over 65 years [22]. Non-
vaccine-type disease however increased, respectively, 68
and 48% in children and adults over 65 years, a phenom-
enon called serotype replacement [1, 22]. The net overall
reduction in IPD was 56% in children and 19% in adults
over 65 years [22]. The introduction of conjugated pneumo-
coccal vaccines not only reduced IPD incidence in vacci-
nated but also in unvaccinated persons [1, 22–24]. This
phenomenon is called the ‘herd protection’ and a conse-
quence of a reduced nasopharyngeal colonization in the
population [1, 22–24].
Safety of pneumococcal PPV and PCV vaccine. Polysacchar-
ide and conjugated pneumococcal vaccine have a compar-
able and high safety profile, with regular local irritation at
the injection site (pain, redness, swelling and limitation of
movement of the injected arm), and rarely systemic side
effects such as fatigue and headache [10, 13].
Pneumococcal vaccination in adults: 2013 UK and France,
and 2014 USA and Spanish recommendations. In the
USA (provided by the ‘Advisory Committee on Immuniza-
tion Practices’ or ACIP) and Spain, PCV-13 followed by a
PPV-23 repeated dose 6–12 months later (and at least 8
weeks later) is recommended for all adults of ≥65 years
old, and in adults of ≥19 years old with immunocom-
promising conditions, functional or anatomic asplenia,
cerebrospinal fluid leaks or cochlear implants [10, 13, 20].
A second PPV-23 repeated dose vaccination may be given
at least 5 years later [10, 13, 20]. Immunodeficiency is
defined as congenital or acquired immunodeficiency, HIV,
haematological malignancies, generalized malignancy,
immunosuppressive treatment, solid-organ transplanta-
tions, CKD and nephrotic syndrome [10, 13]. In previously
PPV-vaccinated persons, a PCV-13 should not be given
before 1 year after the latest PPV vaccine [13, 20].
Pneumococcal vaccination can be co-administered with
trivalent inactivated influenza vaccination [13].
The 2013 French recommendations endorse the ACIP
PCV-13 prime–PPV-23 boost strategy for immunocom-
promised patients, while still advocating a PPV-23 prime
vaccine in non-immunocompromised persons of ≥65
years [19]. The 2013 British NHS recommendations define
a similar target population but only recommend the PPV-
23 vaccine in adults [18].
Cost-effectiveness of pneumococcal vaccination. In 2012,
the CDC estimated the efficacy of PCV-13 in reducing IPD
and pneumonia to be respectively 75 and 13% in adult
HIV/AIDS and dialysis patients [10]. According to these
data, health costs could be reduced by 7.6 million dollars,
1360 quality-adjusted life years (QALY) could be gained
and 57 cases of IPD could be avoided by implementing
the ACIP guidelines in the USA [10].
A 2014 systematic review of available European studies
on cost-effectiveness of PCV-13—which does not yet
include the CAPiTA data—concluded that, given the
limited information and the great variability within and
between studies, no clear conclusions could yet be drawn
on the economical utility of conjugate pneumococcal
vaccination for the entire population or in pre-defined
(immunocompromised) subpopulations [25].
Immune dysfunction in CKD
CKD is associated with hypercytokinaemia and ongoing in-
flammation, predisposing for cardiovascular disease [26].
CKD also results in a decreased innate and adaptive
immune response, predisposing for infections [26, 27]. Dis-
turbances of innate immunity results in inadequate mono-
cyte and neutrophil function and persistent low-grade
inflammation [26, 27]. Disturbances of the adaptive immune
responses result in a decrease in antigen presenting func-
tion, T-cell-mediated immune response and immunological
memory [26, 27]. Consequently, CKD patients are prone to
vaccine hyporesponsiveness, which increases with more ad-
vancing stages of CKD, and with concomitant malnutrition
and immunosuppressive treatment [26–29]. It thus seems
logical to vaccinate CKD patients as early as possible in the
course of their disease [27, 28].
Pneumococcal infections and vaccination in
patients with CKD
Search strategy
A Pubmed search was performed in September 2014 using
the terms (pneumococcal vaccine) and (end-stage renal
disease) or (CKD) or (dialysis) or (transplantation) as well as
a search of the relevant references. All papers providing data
on epidemiology, safety and efficacy of the pneumococcal
vaccine in CKD were included. This resulted in 2 papers on
epidemiology of pneumonia, 2 papers on the epidemiologic-
al effect of vaccination, and 5 trials on pneumococcal vac-
cination for CKD; 2 systematics reviews and 2 additional
papers covering 14 trials for transplant recipients, and 1 sys-
tematic review and 5 additional trials for patients with neph-
rotic syndrome. The results are summarized in Table 1.
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Patients with CKD and immunosuppressive
conditions or medication
General considerations
Data on the immunogenicity, effectiveness and safety of
PPV23 and PCV vaccination in immunocompromised pa-
tients are limited since immunocompromised patients are
typically excluded from pre-licensure studies, and post-li-
censure studies usually include smaller groups of patients
with heterogeneous immune-compromising conditions
(e.g. transplantation, vasculitis and malnutrition) [36, 39].
Consequently, vaccination recommendations for immuno-
compromised patients are mainly extrapolated from what
is known in healthy persons [36].
High-level immunosuppressive conditions occur in the
first 2 months after solid-organ transplantation, HIV with
<200 T4 cells, cancer chemotherapy and treatment with
≥20 mg prednisolone equivalents for ≥14 days or immune
modulators such as TNF-α blockers and rituximab [39].
Vaccination guidelines recommend that specialists who
care for immunocompromised patients take responsibility
for adequate vaccination [39]. Inactivated vaccines, such
as the PCV13 and PPV23, should be administered at least
2 weeks prior to immunosuppression, but vaccination
should never delay the initiation of essential immunosup-
pression [39]. All candidates for solidorgan transplant-
ation should receive pneumococcal vaccination early in
their disease [39].
Serotype coverage in immunocompromised patients by the
PCV-13 and PPV-23
In the USA, in 2010 (10 years after the introduction of the
PCV-7), 50% of IPD among immunocompromised adults
were caused by serotypes included in the PCV-13, and an
additional 21% by serotypes only contained in the PPV-23
[10]. In a Spanish survey between 1996 and 2010, 64%
of IPD was covered by the PCV-13, and the risk for non-
coverage of either the PCV-13 or the PPV-23 was the
highest for immunocompromised patients [43]. In a
Belgian survey on IPD in adults between 2009 and 2011
(2 years after the introduction of PCV-7), 61% of serotypes
were covered by the PCV-13, and an additional 25% by the
PPV-23 [7]. Predisposing conditions for IPD were present in
85% of the patients aged 65 years or older, being renal
failure in 19% and immunosuppressive medication in 14%
[7]. Continuous surveillance remains mandatory since
serotype replacement may cause a decreased serotype
coverage in the future.
Efficacy and safety of pneumococcal vaccination
in immunocompromised patients
Inactivated vaccines apparently have a similar safety
profile but reduced efficacy in immunocompromised patients
[39–41]. This has been demonstrated for the inactivated
trivalent flu vaccine in rheumatological patients receiving
azathioprine, rituximab or infliximab, and for the PPV in
patients with rheumatoid or psoriatic arthritis receiving
methotrexate or rituximab, but not anti-TNF-α treatment
[39–41, 44, 45]. In an RCT comparing the immunogenicity
of PCV-7 and PPV-23 in frail, hospitalized elderly, there was
no clear benefit of one vaccine over the other, and the
ability of both vaccines to elicit an immune response was
strongly negatively affected by frailty [46]. Vaccination does
not trigger disease flares for systemic lupus erythematous
or vasculitis, or rejection in solid-organ recipients, and
should thus not bewithheld for this reason [39].
CKD patients with kidney transplantation
Two reviews [4, 36] summarized 12 trials on pneumococcal
vaccination in renal transplant recipients published before
the end of 2011, and 2 additional trials were published after
2011 [37, 38]. These trials were heterogeneous in vaccination
schedule (7 including 372 patients and 98 controls using
PPV-14; 4 including 118 patients using PPV-23; and 3 includ-
ing 119 patients using various PCV-7-based regimens, either
or not with PPV-23 boosting), patient population (adult or
children, with only 5 trials using controls) and assays and de-
finitions used for serological evaluation (with older non-
specific RIA assays used in more than half of the trials) [4,
36]. Serological vaccine response did not differ significantly
from that observed in the general population, although the
height of antibody titres tended to be lower, and the decline
in antibody titre faster [4, 36], especially in the elderly, and in
those patients receiving tacrolimus instead of cyclosporine or
with an impaired kidney function [38]. As compared with a
single vaccination with PPV, a PCV-7 prime vaccination with
a PPV-23 repeated dose after 1 year did not enhance
immune response [37]. These trials suggest a beneficial
effect of pneumococcal vaccination in renal transplant reci-
pients by electing an increase in antibody titre against at
Table 1. Evidence supporting the use of pneumococcal vaccination in patients with CKD and dialysis, kidney transplant recipients and in patients receiving
immunosuppressive medications
Levels of evidence CKD and dialysis Transplant
Immunosuppressive
medication
1. Randomized controlled trials No data No data No data
2. Retrospective epidemiological
cohort studies
6–16% lower overall mortality [30, 31] No data No data
3. Serological data
• Polysaccharide vaccine Response in ±80%, waning over time
[4, 32–35]
Response in ±80–90%, waning over time [4, 36, 37, 38] ‘Reduced response’
[36, 39–41]
• Conjugated vaccine No data Response in ±77%, waning over time%
[4, 36–38]
‘Reduced response’
[39, 36, 40, 41]
Serotype coverage in the population at risk [7, 10, 42]
1. PCV-13 50–64%
2. PPV-23 Additional 20–25%
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least a part of the serotypes without revealing harm; they do
not yet prove clinical benefit. There are no RCTs with morbid-
ity or mortality endpoints assessing the efficacy of pneumo-
coccal vaccination in renal transplant patients.
CKD patients with nephrotic syndrome
All data on pneumococcal vaccination in patients with
nephrotic syndrome are derived from trials with serologic-
al endpoints in children. There exist no data in adults, nor
epidemiological data or clinical trials linking pneumococ-
cal vaccination with outcome.
In children with nephrotic syndrome, PPV and PCV
vaccine was safe and provoked a good short-term serologic-
al response unless the patients received cyclophosphamide
or other immunomodulatory medications [4, 47–51]. At the
long term, a considerable decline in antibody titres was
observed, especially in those infants with ongoing disease
[4, 47, 51]. A PCV-7 repeated dose vaccination could
provoke a significant increase in sero-titres, especially if not
under treatment with immunomodulatory medications
[50].
Patients with end-stage renal disease treated with
dialysis
The risk for pneumococcal infections in patients with
end-stage renal disease
Mortality is much higher in patients with end-stage renal
disease (ESRD) than that in the general population,
ranging from 63 times higher for those under 25 years to
7 times higher for those over 75 years old [52]. Infections
are the second leading cause of death in ESRD after car-
diovascular disease [53]. Infectious mortality is 21.3/1000
patients years, caused by sepsis and pulmonary infections
in respectively 75 and 20% [53, 54]. Pneumonia incidence
in dialysis patients is 27.9/100 person-years, with a 1-year
survival rate of only 0.51 [55]. As compared with ESRD pa-
tients without pneumonia, pneumonia increases mortality
4.99- and 2.12-fold in respectively the subsequent 6
months and 5 years [55]. An episode of pneumonia also
increases the risk for cardiovascular events 3.02- and
1.45-fold during respectively the subsequent 6 months
and 5 years [55]. Crude pneumonia mortality in ESRD
patients is ∼10- to 16-fold higher than that in general
population [54, 55].
Efficacy of pneumococcal vaccination in patients
with ESRD
Circumstantial evidence from epidemiological data
Two retrospective cohort studies in the USA including
respectively 118 533 haemodialysis patients surviving 2
years on haemodialysis and 36.966 patients surviving 1
year on haemodialysis demonstrated a hazard rate for
mortality of 0.84 [30] to 0.94 [31] for pneumococcal vac-
cination alone and 0.71 [30] to 0.73 [31] for combined
pneumococcal and flu vaccination. This beneficial correl-
ation does not prove causality. It may also be a conse-
quence of e.g. the correlation of higher vaccination rates
and a better overall quality of care [31], or a higher
patients’ self-involvement in the management of their
sickness [30]. Moreover, almost half of the haemodialysis
patients aged over 65 years do not survive for 2 years [52].
Overall, pneumococcal vaccination rates in the dialysis
population range from 21 to 41.8% [30, 31].
Evidence derived from trials with serological endpoints
Data on the serological efficacy of pneumococcal vaccin-
ation in dialysis patients are scare. Until 2004, nine vaccin-
ation studies using the polysaccharide vaccine (PPV-14 in
six, PPV-23 in three) were performed in ESRD patients
whether or not treated with dialysis [4]. The trials were
nonrandomized, antibodies were measured with non-
specific RIA assays, the number of patients included was
small (average 16.7, range 10–33) and the follow-up
usually limited to 6 to 12 months [4]. Overall, a serological
response to at least some of the serotypes was documen-
ted in the majority of patients, which tended to be lower
and more rapidly waning than that in healthy controls [4].
In the only study providing longer follow-up, 7 of 33 pa-
tients vaccinated with the PPV-14 developed IPD over a 5-
year period [32]. This was confirmed in two more recent
trials with the PPV-23, documenting hyporesponsiveness
with associated increased risk for pneumococcal infec-
tions in one-fifth (14 of 66) of the patients [33, 34]. Revac-
cination after 2 years with the PPV-14 in 17 previously
vaccinated patients provoked a two-fold increase in anti-
body levels [35]. The only trial with the conjugated PCV-7
vaccine in 48 children demonstrated an antibody level of
≥0.35 µg/mL against at least one serotype in all patients
[56]. However, more than half of the patients did not
respond with a more than 4-fold rise in antibody levels for
at least five serotypes [56].
Evidence derived from trials with morbidity and mortality
endpoints
There exist no well-powered studies on the effect of
pneumococcal vaccination on morbidity and mortality in
patients treated with dialysis.
Conclusions
In the general population, the PPV decreases the inci-
dence of IPD, and pneumococcal type pneumonia. The
conjugated pneumococcal vaccine provokes a stronger
and more long-lasting immune response than the poly-
saccharide vaccine. PCV efficacy in reducing vaccine-type
pneumonia and IPD in adults has recently been demon-
strated. However, due to serotype replacement, only
50–64% of the serotypes involved in IPD in immunocom-
promised patients were covered by the PCV-13 after the
introduction of universal PCV vaccination in children. This
figure may further decline due to the reduction of circulat-
ing vaccine serotypes by interfering with nasopharyngeal
colonization, serotype replacement and herd immunity
effects.
For CKD patients treated with dialysis, epidemiological
data demonstrate a lower mortality in patients vaccinated
with the (polysaccharide) pneumococcal vaccine, espe-
cially if they were also vaccinated against flu. This correl-
ation does not, however, prove causality. Efficacy data on
pneumococcal vaccination in CKD patients are mainly
derived from smaller studies with serological endpoints.
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Pneumococcal vaccination (either PPV or PCV) seems to
elicit an increase in antibody titres in all subgroups of CKD
patients, that is, however, less pronounced and less long-
lasting than that in the general population. Clinical
outcome dates in CKD patients are lacking.
Currently, there is no solid evidence supporting the re-
commendations to administer CKD patients a pneumo-
coccal vaccination. On the other hand, the burden of
pneumococcal infections in CKD patients is high, the cost
of pneumococcal vaccination is low as compared with the
global health costs in this population and there are no
data indicating potential disadvantages. Awaiting better
evidence, all CKD patients should receive pneumococcal
vaccination, either in a PCV-13 prime–PPV-23 boost sched-
ule, or with only a PPV-23 prime vaccination. The potential
advantage of a re-vaccination after 5 years may be nullified
by the limited life-expectancy of most dialysis patients.
Conflict of interest statement. None declared.
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